NCT03553914View on ClinicalTrials.gov

PLM60 for Peripheral T Cell Lymphoma (PTCL)

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2021

Primary Completion Date

January 31, 2024

Study Completion Date

January 31, 2025

Conditions
Peripheral T Cell Lymphoma
Interventions
DRUG

PLM60

PLM60 will be administered via intravenous infusion in 28-day cycles for up to 7 cycles.

Trial Locations (2)

44718

Gabrail Cancer Center, Canton

Gabrial Cancer Center, Canton

Sponsors
All Listed Sponsors
collaborator

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY

lead

Conjupro Biotherapeutics, Inc.

INDUSTRY